Navigation Links
DuPont Leaders Brief Investors on Agriculture Businesses

DuPont Science Addressing Increased Demand for Food, Feed, Fuel, Materials

DES MOINES, Iowa, Aug. 15 /PRNewswire-FirstCall/ -- DuPont (NYSE: DD) Chairman and CEO Charles O. Holliday, Jr., Executive Vice President & Chief Innovation Officer Thomas M. Connelly, and Group Vice President -- DuPont Agriculture & Nutrition J. Erik Fyrwald today updated investors on DuPont businesses serving the agriculture and biofuels markets.

"Global population growth, rising income and demand for biofuels is driving increased demand for agricultural outputs," Holliday said at the DuPont Global Agriculture Investors' Day. "DuPont is uniquely positioned to meet that challenge due to our multi-discipline science, ability to leverage that science across different industries, and our broad market access and global reach."

Connelly added, "The synergies among agricultural biotechnology, biofuels and biomaterials are creating potential game-changing solutions to the global challenges we face today and significant growth opportunities for DuPont."

The company's core competencies to drive innovation across a number of biotechnology markets include cell biology/physiology, molecular biology (gene discovery, expression and optimization), genomics, proteomics, biochemistry and metabolic engineering.

Noting that DuPont is using biotechnology to deliver advanced plant genetics along with chemistry to improve productivity, quality and yield, Fyrwald reviewed the platform's top pipeline candidates.

"We are advancing a rich pipeline of new products to enhance yield and nutrition," he said, referencing top-performing insect resistant corn, Rynaxypyr(TM) low-dosage insecticide, fungal resistant corn, Optimum(TM) GAT(TM) dual herbicide tolerance and healthier soybean oil.

To more strongly position itself for attractive agricultural markets, DuPont announced last year that it was investing $100 million in savings from a restructuring into its crop genetics research and seed sales and marketing.

"The growth fundamentals in seed markets around the world are outstanding," said Fyrwald. "As a result, we are accelerating our growth investments at a faster rate than the savings from our previously announced restructuring plan."

Approximately $100 million in growth investments will be made in 2007. The investments are targeted at accelerating new product launches, increasing the rate of genetic gain, expanding capacity for plant biotechnology discovery and development, increased sales coverage, and more aggressive promotions. With regard to savings from the restructure program, Fyrwald said DuPont Agriculture & Nutrition will generate savings of approximately $20 million of the $100 million target late in 2007, another $40 million in savings in 2008, and the remaining $40 million in savings in 2009.

Fyrwald noted that for the year 2007, he expects the DuPont Agriculture & Nutrition platform to deliver about 10 percent revenue growth and 20 percent pretax operating income (PTOI) growth before accounting for the accelerated growth investments. Including the investments, PTOI growth would be about 10 percent, compared to a compound annual average growth rate of 14 percent since 2001.

DuPont reaffirmed its outlook for 2007 full-year earnings per share of about $3.15, excluding a $0.06 per share charge for significant items in the first quarter 2007.

A replay of today's presentation and the question and answer session can be found at the Investor Center of the company's website at DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

The DuPont Oval Logo, DuPont(TM), The miracles of science(TM), Rynaxypyr(TM) and Optimum(TM) GAT(TM) are registered trademarks or trademarks of DuPont or its affiliates.


Copyright©2007 PR Newswire.

Related biology technology :

1. CIO Leadership Series: Snap-Ons Moreno offers lessons in IT transformation
2. CIO Leadership Series: Logothetis likes CIOs evolving role
3. CIO Leadership Series: Phil Loftus, Aurora Health Care
4. CIO Leadership Series: Deb Rislow, Gundersen Lutheran
5. Patent ruling doesnt tarnish Wisconsins stem cell leadership
6. CIO Leadership Series: Judy Lemke, Schneider National
7. CIO Leadership Series: Tanya Townsend, Saint Clares Hospital
8. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
9. CIO Leadership Series: Rick Davidson, Manpower
10. CIO Leadership Series: Mike Sauk, UW Hospital and Clinics
11. CIO Leadership Series: Ed Meachen, University of Wisconsin System
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):